Clinical Trial Update: STAT3 DECOY in Head and Neck Cancer [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 early trial evaluating a STAT3 decoy in head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• STAT3 decoy (STAT3 decoy oligonucleotide)

Snippet

Sponsor: University of Pittsburgh | Conditions: Head and Neck Cancer | EARLY_Phase 1 | Status: COMPLETED